advertisement
Abstract #10040 Published in IGR 5-3
A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%
Erdoğan H; Toker İ; Kemal Arıcı M; Aygen A; Topalkara AJapanese Journal of Ophthalmology 2003; 47: 473-478
PURPOSE: To evaluate the short-term additive effects of latanoprost 0.005% and brimonidine 0.2%. METHODS: This study was a randomized, double-masked, crossover study that included 32 patients (32 eyes) with primary open angle glaucoma or exfoliation glaucoma. On baseline day, intraocular pressure (IOP) was measured at 10 a.m. and 11 p.m. Baseline IOP values were obtained by calculating the mean values for both eyes. After this process, latanoprost 0.005% was adminstered once a day during the first five days at 10 p.m. as the first test drug. During the second five days, twice daily brimonidine 0.2% or a placebo, as the second test drug, was added to the latanoprost at 9 a.m. and 10 p.m. After a four-week washout period, latanoprost 0.005% was administered once a day during the first five days at 10 p.m. and, during the second five days, the second test drug, brimonidine or a placebo, was added to the latanoprost, and the two drugs were administered twice a day for five days. RESULTS: During the second five days, although an additional 2.53-3.10 mmHg decrease in IOP was determined in the latanoprost = brimonidine group, there was no additional decrease in the latanoprost + placebo group. CONCLUSIONS: This study showed that brimonidine and latanoprost have an additive IOP-lowering effect in open angle glaucoma patients in the short term.
Dr. H. Erdoğan, Cumhuriyet Üniversitesi Tip Fakültesi, Göz ABD, 58140 Sivas, Turkey. h_erdogan@ttnet.net.tr
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)